The Lipidomic Profile Discriminates Between MASLD and MetALD
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Kai Markus Schneider und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Lipidomics, Fatty Liver, Liver Diseases, Alcoholic, Lipids. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
The recent consensus statement redefined steatotic liver diseases. Metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol‐related liver disease (MetALD) now represent distinct disease entities. However, biomarkers that differentiate MASLD and MetALD remain largely unknown.
Aims
To identify lipidomic biomarkers with discriminatory potential for distinguishing MetALD from MASLD.
Methods
Using the UK Biobank dataset, 40,534 people with available MRI liver scans were analysed. A total of, 11,217 cases with a proton density fat fraction (PDFF) ≥ 5% were identified as having steatotic liver disease. Among these, lipidomic profiles were obtained for 5539 MASLD and 462 MetALD cases. A total of, 250 plasma lipidomic and metabolomic parameters were analysed. Mendelian randomisation (MR) analysis was used to confirm the association between alcohol consumption and the lipidomic biomarkers.
Results
When comparing the top 30 differentially expressed lipidomic biomarkers predicting MetALD compared to MASLD, the majority were related to HDL and were significantly overrepresented at both analysed time points. The top five metabolites were: acetoacetate, 3‐hydroxybutyrate, phospholipids in Large HDL, concentration of large HDL particles, free cholesterol in large HDL. The sensitivity analysis comparing alcohol‐related liver disease to MASLD revealed similar associations, suggesting that the HDL signature is stable over time. Additionally, MR analysis further confirmed that alcohol consumption was associated with increased levels of HDL‐related metabolites.
Conclusion
Our findings indicate that HDL‐centric lipidomic markers, particularly those within the larger and medium HDL subfraction, may differentiate MetALD from MASLD. Further longitudinal and experimental studies are warranted to validate these findings and assess their clinical implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
- Department of Medicine I, Deptartment of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, Dresden, Germany.
- Else Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Kate Townsend Creasy, Rohit Loomba
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- NIH HHS
- Deutsche Krebshilfe
- German researchfoundation
- National Institutes of Health
Zitieren
APA
Schneider, K. M., Cao, F., Huang, H. Y. R., Chen, L., Chen, Y., Gong, R., Raptis, A., Creasy, K. T., Clusmann, J., van Haag, F., Koop, P. H., Guillot, A., Luedde, T., Loomba, R., Francque, S., & Schneider, C. V. (2025). The Lipidomic Profile Discriminates Between MASLD and MetALD. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70012
Vancouver
Schneider KM, Cao F, Huang HYR, Chen L, Chen Y, Gong R, et al. The Lipidomic Profile Discriminates Between MASLD and MetALD. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70012
BibTeX
@article{Schneider2025,
author = {Schneider, Kai Markus and Cao, Feng and Huang, Helen Ye Rim and Chen, Lanlan and Chen, Yazhou and Gong, Rongpeng and Raptis, Anastasia and Creasy, Kate Townsend and Clusmann, Jan and van Haag, Felix and Koop, Paul-Henry and Guillot, Adrien and Luedde, Tom and Loomba, Rohit and Francque, Sven and Schneider, Carolin Victoria},
title = {The Lipidomic Profile Discriminates Between MASLD and MetALD},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70012}
}
EUVIMED